Octreotide.
Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
S W
SW
Lamberts
A J
AJ
van der Lely
W W
WW
de Herder
L J
LJ
Hofland
D000172:Acromegaly / Q000188:drug therapy; D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010182:Pancreatic Diseases / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000188:drug therapy; D017481:Receptors, Somatostatin / Q000145:classification / Q000187:drug effects; D013004:Somatostatin / Q000031:analogs & derivatives*
D018931:Antineoplastic Agents, Hormonal; D005765:Gastrointestinal Agents; D017481:Receptors, Somatostatin; D013004:Somatostatin; D015282:Octreotide